Type 5 Phosphodiesterase Inhibition in Heart Failure. The Next Step**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 22, 2007, Pages 2145-2147

  Goldsmith, Steven R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLIC AMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

BRACHIAL ARTERY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENZYME INHIBITION; FOREARM BLOOD FLOW; HEART FAILURE; HEMODYNAMICS; HUMAN; LONG TERM CARE; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; MECHANORECEPTOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESPIRATORY FUNCTION; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

HEART FAILURE, SYSTOLIC; HUMANS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PULMONARY ARTERY; PURINES; SULFONES; TREATMENT OUTCOME; VASCULAR RESISTANCE; VENTRICULAR FUNCTION, RIGHT;

EID: 36148932890     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.07.075     Document Type: Editorial

References (17)

1. Santayana G. The Life of Reason. Available at: http://en.wikiquote.org/wiki/George_Santayana. Accessed October 23, 2007.
2. Rabe K.F., Tenor H., Dent G., Schudt C., Nakashima M., and Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 266 (1994) L536-L543
3. Galie N., Ghofrani H.A., Torbicki A., et al., Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
4. Michelakis E.D., Tymchak W., Noga M., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108 (2003) 2066-2069
5. Guazzi M., Samaja M., Arena R., Vicenzi M., and Guazzi M.D. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50 (2007) 2136-2144
6. Ponikowski P.P., Chua T.P., Francis D.P., Capucci A., Coats A.J., and Piepoli M.F. Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation 104 (2001) 2324-2330
7. Scott A.C., Francis D.P., Davies L.C., Ponikowski P., Coats A.J., and Piepoli M.F. Contribution of skeletal muscle "ergoreceptors" in the human leg to respiratory control in chronic heart failure. J Physiol 529 (2000) 863-870
8. Guazzi M., Tumminello G., Di Marco F., Fiorentini C., and Guazzi M.D. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 44 (2004) 2339-2348
9. Lewis G.D., Lachman J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115 (2007) 59-66
10. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105 (2002) 2398-2403
11. Cremers B., Scheler M., Maack C., et al. Effects of sildenafil (Viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. J Cardiovasc Pharmacol 41 (2003) 734-743
12. Jackson G., Benjamin N., Jackson N., and Allen M.J. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83 (1999) 13C-20C
13. Herrmann H.C., Chang G., Klugherz B.D., and Mahoney P.D. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 342 (2000) 1622-1626
14. Borlaug B.A., Melenovsky V., Marhin T., Fitzgerald P., and Kass D.A. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112 (2005) 2642-2649
15. Nagendran J., Archer S.L., Soliman D., et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116 (2007) 238-248
16. Kass D. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?. Circulation 116 (2007) 233-235
17. DiBianco R., Shabetai R., Kostuk W., Moran J., Schlant R.C., and Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320 (1989) 677-683